This revised application proposes to conduct a randomized, double blind, placebo-controlled combined laboratory and clinical outcome study to test the efficacy of Prazosin (PZ) in decreasing alcohol craving, anxiety, stress dysregulation and alcohol use outcomes in treatment seeking alcohol dependent (AD) individuals with and without current anxiety disorders (+Anx/-Anx). In previous research we've shown that laboratory exposure to stress and alcohol cues increases alcohol craving, anxiety and stress dysregulation, which in turn, are predictive of subsequent alcohol relapse outcomes. Prazosin, an alpha-1 adrenergic antagonist, known to decrease central norepinephrine and CRF upregulation, decreases stress-induced alcohol reinstatement and alcohol consumption in both dependent rats and in a preliminary study with alcoholic patients. However, the specific mechanisms by which PZ may be decreasing alcohol consumption in humans is not understood. Our preliminary data show that PZ relative to Placebo (PL) decreases stress and cue- induced alcohol craving, anxiety and stress dysregulation in AD individuals, and that such decreases are more pronounced in AD individuals with current anxiety disorders than those without such comorbidity. Thus, in light of previous research and our preliminary findings, we propose a 5-year study that will recruit 150 AD individuals (evenly split by those with and without any current anxiety disorders) to participate in a randomized, double blind, placebo-controlled 12-week clinical laboratory and outcome study. The following specific aims will be addressed: 1) To evaluate the effects of PZ (16 mg, tid) on stress and cue-induced alcohol craving and anxiety, stress dysregulation in the laboratory in AD patients with and without current anxiety disorders;(2)To evaluate the effects of 16mg PZ on alcohol craving, anxiety and stress dysregulation in AD patients with current anxiety disorders as compared to those without anxiety disorders;(3) To determine the efficacy of 12- week PZ treatment on primary alcohol use outcomes, and secondary outcomes including alcohol craving, negative mood symptoms, smoking and sleep;(4) To assess the efficacy of 12-week PZ versus PL treatment on primary alcohol use and secondary outcomes in alcoholics with/without any current anxiety disorders. (5) To examine one-month post-treatment follow-up alcohol use outcomes for enduring short term treatment effects. The role of patient characteristics and laboratory-based craving and stress dysregulation in predicting alcohol treatment outcome will also be explored. If the proposed hypotheses are supported, it will provide evidence for efficacy of Prazosin as a medication for alcoholism, particularly for those with co-morbid anxiety disorders.

Public Health Relevance

Alcoholism is among the top three causes of preventable death and disease in the US (Mokdad et al., 2004; Room et al., 2005) and stress and anxiety disorders play a role in high alcohol relapse risk. The proposed study will test the efficacy of Prazosin, an alpha-1 adrenergic antagonist, versus placebo, in decreasing provoked alcohol craving, normalizing stress dysregulation and reducing alcohol use outcomes in alcoholics with and without anxiety disorders. Findings will have significant implications for developing new treatments for alcoholism, particularly among those with co-morbid anxiety disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Research Project (R01)
Project #
1R01AA020504-01A1
Application #
8297322
Study Section
Health Services Research Review Subcommittee (AA)
Program Officer
Fertig, Joanne
Project Start
2012-09-01
Project End
2017-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
1
Fiscal Year
2012
Total Cost
$544,751
Indirect Cost
$213,725
Name
Yale University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Li, Haisheng; Yao, Zhihui; He, Weifeng et al. (2016) P311 induces the transdifferentiation of epidermal stem cells to myofibroblast-like cells by stimulating transforming growth factor β1 expression. Stem Cell Res Ther 7:175
Xu, Rui; Xia, Hesheng; He, Weifeng et al. (2016) Controlled water vapor transmission rate promotes wound-healing via wound re-epithelialization and contraction enhancement. Sci Rep 6:24596
Xu, Xiaoxiao; Yuan, Hong; Lei, Xu (2016) Activation and Connectivity within the Default Mode Network Contribute Independently to Future-Oriented Thought. Sci Rep 6:21001
Kong, Yi; Xu, Rui; Darabi, Mohammad Ali et al. (2016) Fast and safe fabrication of a free-standing chitosan/alginate nanomembrane to promote stem cell delivery and wound healing. Int J Nanomedicine 11:2543-55
Mackey, Scott; Kan, Kees-Jan; Chaarani, Bader et al. (2016) Genetic imaging consortium for addiction medicine: From neuroimaging to genes. Prog Brain Res 224:203-23
Zhan, Rixing; He, Weifeng; Wang, Fan et al. (2016) Nitric oxide promotes epidermal stem cell migration via cGMP-Rho GTPase signalling. Sci Rep 6:30687
Seo, Dongju; Lacadie, Cheryl M; Sinha, Rajita (2016) Neural Correlates and Connectivity Underlying Stress-Related Impulse Control Difficulties in Alcoholism. Alcohol Clin Exp Res 40:1884-94
Milivojevic, Verica; Fox, Helen C; Sofuoglu, Mehmet et al. (2016) Effects of progesterone stimulated allopregnanolone on craving and stress response in cocaine dependent men and women. Psychoneuroendocrinology 65:44-53
Yao, Zhihui; Yang, Sisi; He, Weifeng et al. (2015) P311 promotes renal fibrosis via TGFβ1/Smad signaling. Sci Rep 5:17032
Blaine, Sara K; Seo, Dongju; Sinha, Rajita (2015) Peripheral and prefrontal stress system markers and risk of relapse in alcoholism. Addict Biol :

Showing the most recent 10 out of 25 publications